Amphetamine-Related DisordersPhase 1NCT02294266
Mephedrone and Alcohol Interactions in Humans
A Phase 1 study testing Mephedrone and alcohol, Mephedrone and Alcohol in people with Amphetamine-Related Disorders and Alcohol-Related Disorders, run by Parc de Salut Mar at 1 site in Spain.
Trial summary
The purposes of this study are 1) to evaluate the pharmacological effects after oral coadministration of mephedrone and alcohol and 2) determine the pharmacokinetics changes of mephedrone and alcohol concentrations after oral coadministration of mephedrone and alcohol. Read more about this study
- Who is it for?
- Ages 18 to 45 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Amphetamine-Related Disorders, Alcohol-Related Disorders
- What is being tested?
- Mephedrone and alcohol, Mephedrone and Alcohol
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 1 siteSpain
- Study dates
- Dec 2014to Mar 2015
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Understanding and accepting the study procedures and signing the informed consent.
- Male adults volunteers (18-45 years old).
- Clinical history and physical examination demonstrating no organic or psychiatric disorders.
- The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
- Recreational use of amphetamines, ecstasy and hallucinogen derivate, mephedrone or other cathinone on at least 6 occasions (two in the previous year) without any adverse reactions.
- Recreational use of alcohol (ethanol). Previous experience in acute alcohol intoxication.
- Extensive metabolizer or intermediate metabolizer phenotype for cytochrome P-450-2D6 (CYP2D6) activity determined using dextromethorphan as a selective probe drug.
- The weight does not exceed 15% of ideal weight that applies according to size and will be between 60 and 100 Kg. Minor variations will be accepted as normal limits, if the researchers considered it clinically insignificant.
Who cannot join
- Not meeting the inclusion criteria.
- Daily consumption >20 cigarettes and >4 standard units of ethanol.
- Regular use of any drug in the month prior to the study sessions. The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.
- Presence of major psychiatric disorders.
- Present history of abuse or drug dependence (except for nicotine dependence).
- Past history of drug dependence (except for nicotine dependence). Past history of drug abuse could be included.
Show all 12Show fewer
- Having suffered any organic disease or major surgery in the three months prior to the study start.
- Blood donation 12 weeks before or participation in other clinical trials with drugs in the previous 4 weeks.
- Subjects with intolerance or serious adverse reactions to drugs or amphetamines, ecstasy and hallucinogen derivate, mephedrone or other cathinone.
- History or clinical evidence of gastrointestinal, liver, renal or other disorders which may lead to suspecting a disorder in drug absorption, distribution, metabolism or excretion, or that suggest gastrointestinal irritation due to drugs.
- Subjects unable to understand the nature, consequences of the study and the procedures requested to be followed.
- Subjects with positive serology to Hepatitis B, C or HIV.
Trial locations and contacts
1 site in 1 country.
Spain1 site
Institut Hospital del Mar d'Investigacions Mèdiques-IMIM. Parc de Salut Mar.
Barcelona, Barcelona, 08003
About this study
Official title: Mephedrone and Alcohol Interactions After Single-dose Administration in Humans
The purposes of this study are 1) to evaluate the pharmacological effects after oral coadministration of mephedrone and alcohol and 2) determine the pharmacokinetics changes of mephedrone and alcohol concentrations after oral coadministration of mephedrone and alcohol.
Read the detailed description
Mephedrone (4-methylmetcathinone, 4-MMC) is a new psychoactive substance (NPS). Mephedrone is frequently used in combination with alcohol. At present, the effects of the interaction between mephedrone and alcohol in humans have not been previously evaluated in randomized controlled clinical trials.
The aims of this study are 1) to evaluate the pharmacological effects after oral coadministration of mephedrone and alcohol and 2) determine the pharmacokinetics changes of mephedrone and alcohol concentrations after oral coadministration of mephedrone and alcohol.
- Being tested
- Mephedrone and alcohol, Mephedrone, Alcohol, Placebo
- Medical subject headings
- Amphetamine-Related Disorders, Alcohol-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mephedrone and alcoholDrug
Also called 4-methylmetcathinone; 4-MMC, Alcohol
Single oral dose mephedrone
Single oral dose alcohol
MephedroneDrug
Also called 4-methylmetcathinone; 4-MMC
Single oral dose mephedrone
AlcoholDrug
Single oral dose alcohol
PlaceboDrug
Also called Non-active treatment
Single oral dose placebo
| Study group | Role | What they receive |
|---|---|---|
| Mephedrone and alcohol | Experimental | Mephedrone 200 mg, single dose, oral administration
Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration Receives: Drug: Mephedrone and alcohol |
| Mephedrone | Active comparator | Mephedrone 200 mg, single dose, oral administration
Lemon-flavoured water (350 ml), single dose, oral administration Receives: Drug: Mephedrone |
| Alcohol | Active comparator | Lactose 200 mg, single dose, oral administration
Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration Receives: Drug: Alcohol |
| Placebo | Placebo comparator | Lactose 200 mg, single dose, oral administration
Lemon-flavoured water (350 ml), single dose, oral administration Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in drunkenness and drowsiness and effects
Drunkenness and drowsiness effects will be measured using rate scales (visual analogue scales).
Measured: From pre-dose (baseline, 0h) to 6h post-dose
Secondary outcomes (12)
Change in other subjective effects
Subjective effects will be measured using rate scales (visual analogue scales, the Addiction Research Center Inventory and the Evaluation of the Subjective Effects of Substances with Abuse Potential Questionnaires). All these instruments include measures of euphoria-good effects and other feelings induced by psychostimulants and alcohol.
Measured: From pre-dose (baseline, 0h) to 6h post-dose
Change in blood pressure
Systolic and diastolic blood pressure
Measured: From pre-dose (baseline, 0h) to 6h post-dose
Change in psychomotor function
Psychomotor function will be measured using Critical tracking task (CTT) and Divided Attention Task (DAT).
Measured: From pre-dose (baseline, 0h) to 1, 1.5 and 4h post-dose
Change in memory function
Memory function will be measured using Spatial Memory Task (SMT).
Measured: From pre-dose (baseline, 0h) to 1, 1.5 and 4h post-dose
Area Under the Concentration-Time Curve (AUC 0-24h)
Calculation of AUC of the concentrations of mephedrone and its metabolites in blood and urine.
Measured: From pre-dose (baseline, 0h) to 0.15, 0.3, 0.45, 1, 1.5, 2, 3, 4, 6, 8, and 10h post-dose
Area Under the Concentration-Time Curve (AUC 0-10h)
Calculation of AUC of the concentrations of alcohol in blood.
Measured: From pre-dose (baseline, 0h) to 0.45, 1, 1.5, 2, 3, 4, 6, 8, and 10h post-dose
Number of Participants with Serious and Non-Serious Adverse Events
Collection of adverse effects spontaneously reported by the participants and/or observed by the investigators.
Measured: 7 days after each
Elimination hal-life
Calculation of elimination hal-life from concentrations of mephedrone and its metabolites in blood and urine.
Measured: From pre-dose (baseline, 0h) to 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24h post-dose
Elimination hal-life
Calculation of elimination hal-life from concentrations of alcohol in blood.
Measured: From pre-dose (baseline, 0h) to 0.45, 1, 1.5, 2, 3, 4, 6, 8, an 10h post-dose
Change in heart rate
Measure of heart rate
Measured: From pre-dose (baseline, 0h) to 6h post-dose
Change in pupil diameter
Measure of pupil diameter
Measured: From pre-dose (baseline, 0h) to 6h post-dose
Change in oral temperature
Measure of oral temperature
Measured: From pre-dose (baseline, 0h) to 6h post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2014 (estimated)
- Study startDec 2014
- Primary completionMar 2015
- Study completionMar 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Amphetamine-Related DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Parc de Salut Mar
- Sponsor type
- University, hospital or other
- Collaborators
- Instituto de Salud Carlos III
- Responsible party
- Sponsor
- Investigators
- Magí Farré, MD, PhD, Principal investigator, Institut Hospital del Mar d'Investigacions Mèdiques-IMIM. Parc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02294266
- Sponsor's protocol ID
- IMIMFTCL/MEF/2
- Status last verified
- Oct 2015
- First submitted
- 17 Nov 2014
- Last updated
- 8 Oct 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Papaseit E, Perez-Mana C, de Sousa Fernandes Perna EB, Olesti E, Mateus J, Kuypers KP, Theunissen EL, Fonseca F, Torrens M, Ramaekers JG, de la Torre R, Farre M. Mephedrone and Alcohol Interactions in Humans. Front Pharmacol. 2020 Jan 28;10:1588. doi: 10.3389/fphar.2019.01588. eCollection 2019.
PubMed 32063845
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mephedrone and Alcohol Interactions After Single-dose Administration in Humans
- ClinicalTrials.gov ID
- NCT02294266
- Acronym / sponsor ID
- IMIMFTCL/MEF/2
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Parc de Salut MarUniversity, hospital or other
- Collaborators
- Instituto de Salud Carlos III
- Study start
- Dec 2014
- Primary completion
- Mar 2015 (actual)
- Study completion
- Mar 2015 (actual)
- First posted
- 19 Nov 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purposes of this study are 1) to evaluate the pharmacological effects after oral coadministration of mephedrone and alcohol and 2) determine the pharmacokinetics changes of mephedrone and alcohol concentrations after oral coadministration of mephedrone and alcohol.
Detailed description
Mephedrone (4-methylmetcathinone, 4-MMC) is a new psychoactive substance (NPS). Mephedrone is frequently used in combination with alcohol. At present, the effects of the interaction between mephedrone and alcohol in humans have not been previously evaluated in randomized controlled clinical trials.
The aims of this study are 1) to evaluate the pharmacological effects after oral coadministration of mephedrone and alcohol and 2) determine the pharmacokinetics changes of mephedrone and alcohol concentrations after oral coadministration of mephedrone and alcohol.
Study design
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Mephedrone and alcohol | Experimental | Drug: Mephedrone and alcoholMephedrone 200 mg, single dose, oral administration Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration |
| Mephedrone | Active comparator | Drug: MephedroneMephedrone 200 mg, single dose, oral administration Lemon-flavoured water (350 ml), single dose, oral administration |
| Alcohol | Active comparator | Drug: AlcoholLactose 200 mg, single dose, oral administration Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration |
| Placebo | Placebo comparator | Drug: PlaceboLactose 200 mg, single dose, oral administration Lemon-flavoured water (350 ml), single dose, oral administration |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (8 listed)
- Understanding and accepting the study procedures and signing the informed consent.
- Male adults volunteers (18-45 years old).
- Clinical history and physical examination demonstrating no organic or psychiatric disorders.
- The ECG and general blood and urine laboratory tests performed before the study should be within normal ranges. Minor or occasional changes from normal ranges are accepted if, in the investigator's opinion, considering the current state of the art, they are not clinically significant, are not life-threatening for the subjects and do not interfere with the product assessment. These changes and their non-relevance will be justified in writing specifically.
- Recreational use of amphetamines, ecstasy and hallucinogen derivate, mephedrone or other cathinone on at least 6 occasions (two in the previous year) without any adverse reactions.
Key exclusion criteria (12 listed)
- Not meeting the inclusion criteria.
- Daily consumption >20 cigarettes and >4 standard units of ethanol.
- Regular use of any drug in the month prior to the study sessions. The treatment with single or limited doses of symptomatic medicinal products in the week prior to the study sessions will not be a reason for exclusion if it is calculated that it has been cleared completely the day of the experimental session.
- Presence of major psychiatric disorders.
- Present history of abuse or drug dependence (except for nicotine dependence).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mephedrone and alcoholAlso: 4-methylmetcathinone; 4-MMC, AlcoholSingle oral dose mephedrone Single oral dose alcohol | Drug | Mephedrone and alcohol |
| MephedroneAlso: 4-methylmetcathinone; 4-MMCSingle oral dose mephedrone | Drug | Mephedrone |
| AlcoholSingle oral dose alcohol | Drug | Alcohol |
| PlaceboAlso: Non-active treatmentSingle oral dose placebo | Drug | Placebo |
Primary outcome
Change in drunkenness and drowsiness and effects
Time frame: From pre-dose (baseline, 0h) to 6h post-dose
Drunkenness and drowsiness effects will be measured using rate scales (visual analogue scales).
12 secondary outcomes
Change in other subjective effects
Time frame: From pre-dose (baseline, 0h) to 6h post-dose
Change in blood pressure
Time frame: From pre-dose (baseline, 0h) to 6h post-dose
Change in psychomotor function
Time frame: From pre-dose (baseline, 0h) to 1, 1.5 and 4h post-dose
Change in memory function
Time frame: From pre-dose (baseline, 0h) to 1, 1.5 and 4h post-dose
Area Under the Concentration-Time Curve (AUC 0-24h)
Time frame: From pre-dose (baseline, 0h) to 0.15, 0.3, 0.45, 1, 1.5, 2, 3, 4, 6, 8, and 10h post-dose
Area Under the Concentration-Time Curve (AUC 0-10h)
Time frame: From pre-dose (baseline, 0h) to 0.45, 1, 1.5, 2, 3, 4, 6, 8, and 10h post-dose
Number of Participants with Serious and Non-Serious Adverse Events
Time frame: 7 days after each
Elimination hal-life
Time frame: From pre-dose (baseline, 0h) to 0.15, 0.30, 0.45, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24h post-dose
Elimination hal-life
Time frame: From pre-dose (baseline, 0h) to 0.45, 1, 1.5, 2, 3, 4, 6, 8, an 10h post-dose
Change in heart rate
Time frame: From pre-dose (baseline, 0h) to 6h post-dose
Change in pupil diameter
Time frame: From pre-dose (baseline, 0h) to 6h post-dose
Change in oral temperature
Time frame: From pre-dose (baseline, 0h) to 6h post-dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2015.
- Derived from this study: PubMed 32063845Papaseit E, Perez-Mana C, de Sousa Fernandes Perna EB, Olesti E, Mateus J, Kuypers KP, Theunissen EL, Fonseca F, Torrens M, Ramaekers JG, de la Torre R, Farre M. Mephedrone and Alcohol Interactions in Humans. Front Pharmacol. 2020 Jan 28;10:1588. doi: 10.3389/fphar.2019.01588. eCollection 2019.
Related trials for Amphetamine-Related Disorders
RecruitingPhase 2
MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder
Post Traumatic Stress Disorder
Not yet recruitingPhase 2
Psilocybin Therapy for Methamphetamine Use Disorder and HIV
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Recruiting
Applying Low-Intensity Focused Ultrasound in Treating Severe Substance Use Disorder: Tolerability and Effectiveness
Opioid Use Disorder, Severe, Amphetamine Use Disorder
RecruitingPhase 2
Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder
Cocaine Use Disorder
Active, not recruitingPhase 1/2
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Amphetamine-Related Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Magí Farré, MD, PhD principal investigator
Institut Hospital del Mar d'Investigacions Mèdiques-IMIM. Parc
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Mephedrone and alcohol, Mephedrone and Alcohol in people with Amphetamine-Related Disorders and Alcohol-Related Disorders, run by Parc de Salut Mar at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in drunkenness and drowsiness and effects (time frame: From pre-dose (baseline, 0h) to 6h post-dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02294266, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2015.